Trial Profile
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary) ; Ritonavir (Primary)
- Indications Hepatitis D
- Focus Adverse reactions; Therapeutic Use
- Acronyms LOWR HDV - 3
- 14 Nov 2023 Results of pooled analysis from LOWR-3 , LIMT-1 and LIFT-1, comparing different combinations of novel HDV therapies and assessing their anti-HDV effectiveness, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Apr 2018 Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy was developed using data from LOWR HDV 3 study; results presented at The International Liver Congress 2018
- 24 Oct 2017 Results of dynamic modelling presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.